RUA Life Sciences PLCLSE: RUA

AorTech Receives Record Polym

· Issued by RUA Life Sciences PLC
RNS Number : 9619C
Aortech International PLC
24 November 2009
 

For Immediate Release

November 24, 2009

AorTech Receives Record Polymer Order

AorTech International plc (AIM: AOR) the biomaterials and medical device development company, today announces the receipt of a $503,000 Elast-Eon™ polymer order, the largest in the company's history.

This order for Elast-Eon 2A reflects the demand of a single customer through to May 31, 2010. Approximately $300,000 will be billed prior to December 31, 2009. 

"This polymer order represents a step forward in the growth of the recurring manufacturing revenues associated with our polymer business. As AorTech's polymer business segment continues to mature, it will be augmented by our Elast-Eon-based medical device component business. 

"This increase in polymer demand is comfortably within the capacity of our state-of-the-art 1,900 square meter manufacturing facility, which since its opening in January of 2006 has maintained a perfect quality and delivery record," said Frank Maguire, AorTech Chief Executive Officer.  

AorTech develops and manufactures biostable, implantable polymers, including Elast-Eon and newly introduced ECSil™.  Elast-Eon is the world's leading long-term implantable copolymer. With clinical experience of almost four years and over a million long-term human implants, Elast-Eon is currently used in cardiology, orthopaedic, urological and gastroenterological applications, including pacing leads, cardiac cannulae and stents. Devices manufactured from Elast-Eon have multiple US FDA PMA approvals, CE Marks, Australian TOH and Japanese Ministry of Health approvals.

Elast-Eon's biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. It can be processed using conventional thermoplastic extrusion and moulding techniques, as well as Reaction Injection Moulding (RIM). The firm's ISO-certified facility produces a range of Elast-Eon and ECSil materials in a variety of specific formulations for use in medical devices and components.

-Ends-

For further information please contact:

AorTech International plc

Frank Maguire, Chief Executive

Tel: + 1 801 201 4336

Evolution Securities
Bobbie Hilliam

Tel: +44 20 7071 4300

Chris Clarke

Tel: +44 20 7071 4300

AorTech International plc

Sarah Price, Investor Relations

Tel: + 1 801 550 4349

e-mail [email protected]


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCILFVALRLVFIA

RUA Life Sciences PLC on 6ix

Earlier from RUA Life Sciences

Later from RUA Life Sciences

All RUA Life Sciences news releases